Key result
Lignocaine in therapeutic dosages carries no risk of exit block in pacemaker-treated patients, but is contraindicated in those with AV block II and III without a pacemaker.
Why the study?
Does lignocaine in therapeutic anti-arrhythmic dosages increase the risk of exit block in patients treated with a pacemaker?
Does lignocaine in therapeutic anti-arrhythmic dosages increase the risk of exit block in patients treated with a pacemaker?
Lignocaine can be safely used in pacemaker-treated patients without risk of exit block, but remains contraindicated in unpaced patients with AV block II and III.
Answers are grounded in this paper and cite their sources.
May support lignocaine use in paced patients without exit block risk; leaves open prospective confirmation in unpaced AV block II/III.
The present study was carried out to see if lignocaine in therapeutic anti-arrhythmic dosages given to pacemaker-treated patients involved any risks of exit block. We conclude that such risk does not exist. However, we consider that lignocaine is contraindicated in patients with AV block II and III not treated with a pacemaker.
No takes yet. Share an insight, caveat, or question.
Rydén et al. (1969) studied this question. Lignocaine in therapeutic dosages carries no risk of exit block in pacemaker-treated patients, but is contraindicated in those with AV block II and III without a pacemaker.
Synapse has enriched 10 related papers. Consider them for comparative context: